Cervical Cancer Patient-Derived Xenograft Models

Introduction to Patient-Derived Xenograft Models

Cervical cancer patient-derived xenograft (PDX) models are a vital resource for cancer research, designed to mimic the biological characteristics of cervical cancer. By transplanting tumor tissues harvested directly from patients into immunodeficient mice, these models preserve the genomic, histological, and molecular features of the original tumors. As a result, they provide an invaluable platform for evaluating therapeutic strategies and exploring the potential for personalized medicine.

Fig. 1 A brief experimental diagram of the patient-derived xenograft (PDX) model.(Tanaka T, et al., 2021)

Characteristics of Cervical Cancer PDX Models

Cervical cancer PDX models are established using fresh tumor samples obtained from patients, typically through surgical resection or biopsy. The transplantation is done into specific sites within immunodeficient mice, such as subcutaneously or in the renal capsule, allowing for the maintenance of the tumor microenvironment and metastatic characteristics. These models retain the heterogeneity found in the original tumors, making them particularly beneficial for understanding the complexity of cervical cancer biology.

Our Services

Construction Protocols for Cervical Cancer PDX Models

• Sample Procurement: We procure fresh tumor tissues from cervical cancer patients, ensuring that high-quality samples are available for transplantation.
• Transplantation Techniques: Our team expertly implants the tumor tissues into immunocompromised mice. Depending on the research goals, we can utilize various transplantation sites. While subcutaneous models are commonly employed for practical reasons, kidney capsule models can be utilized for better preservation of tumor heterogeneity.
• Success Rates: The establishment of our cervical cancer PDX models is influenced by several factors, including tumor characteristics and the specifics of the transplantation site. Our success rates typically range between 60% and 63%, demonstrating the effectiveness of our protocols.

Validation of PDX Models

• Histological and Immunohistochemical Analysis: We conduct thorough assessments to confirm the morphological similarities between the PDX models and the original tumors, including analysis of cellular composition and vascular structures.
• Genomic and Exome Sequencing: Our team performs comprehensive sequencing to verify that the models retain the genetic mutations and expression patterns present in the original tumors. Common mutation hotspots analyzed include genes such as TP53 and CDKN2A.
• Drug Sensitivity Testing: We evaluate the responsiveness of our PDX models to chemotherapy and targeted therapies, allowing us to accurately predict patient-specific treatment responses.

Applications of Cervical Cancer PDX Models

Evaluating Treatment Strategies

These models aid in the assessment of both conventional chemotherapy and novel therapeutic approaches. For instance, recent studies have explored the potential of combining immunotherapies with traditional treatments in PDX models derived from patients with advanced cervical cancer.

Facilitating Personalized Medicine

By analyzing the genetic profiles of PDX tumors, researchers can identify molecular subtypes of cervical cancer that correlate with patient outcomes, thereby providing a foundation for tailored treatment plans.

Testing Novel Therapies

Researchers utilize these models to screen new drugs and understand their mechanisms of action, making them essential tools for drug development.

Alfa Cytology is your ideal partner for cervical cancer PDX model development, leveraging our extensive experience and expertise in oncology research. We offer stock models, customizable options, and collaborative R&D services to meet your specific needs. From solutions to reports, we provide comprehensive support. For inquiries or custom model development, please contact us.

For research use only.